Yeah I really like all the potential here...do not really see it dropping below 2.7 though given there is a good amount of support there... so buying here is best value...
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling